Clinical Trial Update: Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating nintedanib for reducing epistaxis in patients with hereditary hemorrhagic telangiectasia and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Hemorrhagic Telangiectasia

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Dr. Romain Lazor | Conditions: Telangiectasia, Hereditary Hemorrhagic | Phase 2 | Status: RECRUITING